MCAM and cancer: Figures 6a and h show that ratios of phospho-AKT (Ser 473)/AKT in tumors of the METCAM clone 2D was not statistically significantly different from those in tumors of the control (vector) clone 3D, indicating that METCAM over-expression did not affect the survival pathway of SK-OV-3 cancer cells during in vivo tumorigenesis.